Earn $20 cash for participating in a new product evaluation. Participation in the trial should take approximately 45 minutes. Northwest Indianapolis.

Condition:   Schizophrenia
Interventions:   Drug: Risperidone;   Drug: Placebo;   Drug: LY2140023
Sponsor:   Eli Lilly and Company
Not yet recruiting - verified March 2010

Condition:   Asthma
Interventions:   Drug: Fluticasone Furoate/GW642444;   Drug: Fluticasone furoate
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Retinal Vein Occlusions
Interventions:   Drug: Avastin;   Drug: Osurdex;   Drug: Avastin
Sponsor:   Maturi, Raj K., M.D., P.C.
Recruiting - verified March 2010

Conditions:   Autistic Disorder;   Asperger's Disorder;   Pervasive Developmental Disorder NOS
Interventions:   Drug: D-cycloserine;   Drug: Placebo
Sponsors:   Indiana University;   Department of Defense
Recruiting - verified March 2010

Conditions:   Mild Cognitive Impairment;   Alzheimer's Disease
Intervention:  
Sponsors:   Alzheimer's Disease Cooperative Study (ADCS);   National Institute on Aging (NIA);   National Institutes of Health (NIH)
Not yet recruiting - verified March 2010

Condition:   Ovarian Cancer
Interventions:   Drug: olaparib;   Drug: paclitaxel;   Drug: carboplatin
Sponsor:   AstraZeneca
Recruiting - verified March 2010

Condition:   Adenocarcinoma of the Breast
Intervention:  
Sponsor:   Indiana University
Not yet recruiting - verified February 2010

Condition:   Triple Negative Breast Cancer
Interventions:   Drug: Cisplatin;   Drug: PF-01367338;   Drug: Cisplatin
Sponsors:   Hoosier Oncology Group;   Pfizer
Recruiting - verified February 2010

Condition:   Bowel Preparation
Interventions:   Drug: PicoPrep;   Drug: HalfLytely
Sponsor:   Ferring Pharmaceuticals
Not yet recruiting - verified February 2010

Condition:   Pregnancy Outcome Trends in Low-resource Geographic Areas
Intervention:   Other: There is no intervention associated with this study.
Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified December 2009

Condition:   Urothelial Carcinoma
Interventions:   Drug: Docetaxel;   Drug: ASA404
Sponsors:   Hoosier Oncology Group;   Novartis Pharmaceuticals
Not yet recruiting - verified February 2010

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: NN1250;   Drug: insulin glargine
Sponsor:   Novo Nordisk
Recruiting - verified March 2010

Condition:   Hepatitis C, Chronic
Interventions:   Drug: RO5024048;   Drug: peginterferon alfa-2a [Pegasys];   Drug: Ribavirin [Copegus]
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Condition:   Sarcoma
Interventions:   Biological: cixutumumab;   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: irinotecan hydrochloride;   Drug: temozolomide;   Drug: vincristine sulfate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Major Depressive Disorder
Interventions:   Drug: OPC-34712 + ADT;   Drug: Placebo + ADT
Sponsor:   Otsuka Pharmaceutical Development & Commercialization, Inc.
Recruiting - verified March 2010

Condition:   Osteoarthritis
Intervention:  
Sponsor:   Biomet, Inc.
Not yet recruiting - verified March 2010

Condition:   Parkinson's Disease
Interventions:   Drug: Rasagiline;   Drug: Placebo
Sponsor:   Teva Pharmaceutical Industries
Recruiting - verified March 2010

Condition:   Hypertriglyceridemia
Interventions:   Drug: AMR101 (ethyl icosapentate);   Drug: AMR101 (ethyl icosapentate);   Drug: Placebo
Sponsor:   Amarin Pharma Inc.
Recruiting - verified February 2010

Condition:   Chronic Obstructive Pulmonary Disease
Interventions:   Drug: Aclidinium bromide;   Drug: Aclidinium bromide;   Drug: Placebo
Sponsors:   Forest Laboratories;   Almirall, S.A.
Recruiting - verified February 2010

Condition:   Neuroblastoma
Interventions:   Biological: aldesleukin;   Biological: monoclonal antibody Ch14.18;   Biological: sargramostim;   Drug: isotretinoin;   Other: laboratory biomarker analysis
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Arthritis, Rheumatoid
Interventions:   Drug: CP-690,550;   Drug: CP-690,550;   Drug: Disease-modifying antirheumatic drug
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Alzheimer's Disease
Intervention:   Drug: Semagacestat
Sponsor:   Eli Lilly and Company
Recruiting - verified March 2010

Condition:   Renal Cell Carcinoma
Interventions:   Drug: Everolimus;   Drug: BNC105P;   Drug: Everolimus;   Drug: BNC105P
Sponsors:   Hoosier Oncology Group;   Bionomics Limited
Recruiting - verified February 2010

Condition:   Essential Hypertension
Interventions:   Drug: TAK-491 and chlorthalidone;   Drug: TAK-491 and chlorthalidone;   Drug: olmesartan medoxomil-hydrochlorothiazide
Sponsor:   Takeda Global Research & Development Center, Inc.
Recruiting - verified February 2010

Condition:   Lymphoma
Interventions:   Biological: bleomycin sulfate;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: prednisone;   Drug: vincristine sulfate;   Drug: vinorelbine ditartrate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Open-Angle Glaucoma;   Ocular Hypertension
Interventions:   Drug: Preservative-Free MK2452 (Tafluprost);   Drug: Comparator: timolol
Sponsor:   Merck
Recruiting - verified March 2010

Conditions:   Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin
Interventions:   Drug: brentuximab vedotin;   Drug: rifampin;   Drug: midazolam;   Drug: ketoconazole;   Drug: brentuximab vedotin
Sponsor:   Seattle Genetics, Inc.
Recruiting - verified February 2010

Conditions:   Mantle Cell Lymphoma;   Non-Hodgkin's Lymphoma
Interventions:   Drug: Lenalidomide;   Other: Placebo
Sponsor:   Celgene Corporation
Recruiting - verified March 2010

Condition:   Hodgkin Lymphoma
Intervention:   Drug: Everolimus (RAD001)
Sponsor:   Novartis
Recruiting - verified March 2010

Condition:   Hepatitis C, Chronic
Interventions:   Drug: Boceprevir (SCH 503034);   Drug: erythropoietin;   Biological: Peginterferon alfa-2b (SCH 54031);   Drug: Ribavirin (SCH 18908)
Sponsor:   Schering-Plough
Recruiting - verified March 2010

Condition:   Acne Vulgaris
Interventions:   Drug: Tazarotene foam;   Drug: Vehicle Foam
Sponsor:   Stiefel, a GSK Company
Recruiting - verified February 2010

Condition:   Sarcoma
Interventions:   Biological: bevacizumab;   Biological: filgrastim;   Biological: pegfilgrastim;   Drug: docetaxel;   Drug: gemcitabine hydrochloride;   Other: placebo
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Endometrial Cancer
Interventions:   Drug: MEK inhibitor AZD6244;   Other: laboratory biomarker analysis
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Arthritis, Psoriatic
Interventions:   Drug: placebo;   Drug: ustekinumab;   Drug: ustekinumab;   Drug: placebo;   Drug: ustekinumab;   Drug: ustekinumab;   Drug: placebo;   Drug: ustekinumab
Sponsor:   Centocor, Inc.
Recruiting - verified February 2010

Condition:   Melanoma
Interventions:   Drug: Tasisulam;   Drug: Paclitaxel
Sponsor:   Eli Lilly and Company
Recruiting - verified March 2010

Condition:   Relapsing-Remitting Multiple Sclerosis
Interventions:   Drug: ACT-128800;   Drug: Placebo
Sponsor:   Actelion
Recruiting - verified February 2010

Condition:   Malignant Melanoma
Interventions:   Drug: RO5185426;   Drug: dacarbazine
Sponsor:   Hoffmann-La Roche
Recruiting - verified February 2010

Conditions:   Lymphoma;   Lymphoproliferative Disorder
Interventions:   Other: biologic sample preservation procedure;   Other: informational intervention
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Acute Coronary Syndrome;   Atherosclerosis;   Cardiovascular Disease;   Coronary Heart Disease
Interventions:   Drug: Darapladib 160 mg;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Attention-Deficit/Hyperactivity Disorder
Interventions:   Drug: extended-release guanfacine hydrochloride;   Drug: placebo;   Drug: extended-release guanfacine hydrochloride
Sponsor:   Shire Pharmaceutical Development
Recruiting - verified March 2010

Condition:   Sexual Dysfunctions, Psychological
Interventions:   Drug: flibanserin;   Drug: placebo;   Drug: placebo
Sponsor:   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010

Condition:   Posttraumatic Stress Disorder (PTSD)
Interventions:   Drug: orvepitant;   Other: Placebo
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Sexual Dysfunctions, Psychological
Interventions:   Drug: Flibanserin;   Drug: Placebo
Sponsor:   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010

Condition:   Psoriasis
Interventions:   Drug: Etanercept ONLY;   Drug: Methotrexate and Etanercept
Sponsors:   Amgen;   Immunex Corporation
Recruiting - verified March 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions:   Drug: belinostat;   Drug: carboplatin
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Biological: cetuximab;   Biological: cixutumumab;   Drug: carboplatin;   Drug: paclitaxel
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Intervention:   Drug: LY573636
Sponsor:   Eli Lilly and Company
Recruiting - verified February 2010

Condition:   Coronary Artery Disease
Interventions:   Drug: Apadenoson;   Drug: Adenosine
Sponsors:   PGxHealth, LLC;   PPD
Recruiting - verified March 2010

Condition:   Human Papillomavirus Infection
Interventions:   Biological: V503;   Biological: Comparator: Menactra™ (Concomitant);   Biological: Comparator: Adacel™ (concomitant);   Biological: Comparator: Menactra™ (Non-Concomitant);   Biological: Comparator: Adacel™ (Non-concomitant)
Sponsor:   Merck
Recruiting - verified March 2010

Condition:   Acute Myeloid Leukemia
Intervention:   Drug: Compound AC220
Sponsor:   Ambit Biosciences Corporation
Recruiting - verified March 2010

Condition:   Castrate-Resistant Prostate Cancer
Intervention:   Drug: Lenalidomide (CC-5013) 10mg, 15mg, 20mg, 25mg and their respective matching placebo capsules for oral administration
Sponsor:   Celgene Corporation
Recruiting - verified March 2010

Condition:   Liver Cancer
Interventions:   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: vincristine sulfate;   Procedure: liver transplantation;   Procedure: therapeutic conventional surgery
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Haemophilia A
Interventions:   Drug: recombinant factor VIII (N8);   Drug: recombinant factor VIII (N8)
Sponsor:   Novo Nordisk
Recruiting - verified March 2010

Conditions:   Brain and Central Nervous System Tumors;   Neurotoxicity
Interventions:   Drug: temozolomide;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Other: Side-effect questionnaires;   Other: research blood samples
Sponsors:   University of Chicago;   Translational Breast Cancer Reserach Consortium;   National Institutes of Health (NIH)
Recruiting - verified February 2010

Condition:   Coronary Artery Disease
Interventions:   Drug: Placebo & Aspirin;   Drug: Clopidogrel & Aspirin, Prasugrel & Aspirin
Sponsors:   Harvard Clinical Research Institute;   Abbott;   Boston Scientific Corporation;   Bristol-Myers Squibb;   Sanofi-Synthelabo;   Cordis Corporation;   Eli Lilly and Company;   Daiichi Sankyo Inc.;   Medtronic
Recruiting - verified March 2010

Condition:   Endometrial Cancer
Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: ixabepilone;   Drug: paclitaxel;   Drug: temsirolimus
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Acute Myelogenous Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Chronic Lymphocytic Leukemia;   Myelodysplasia;   Non-Hodgkin's Lymphoma;   Hodgkin's Disease;   Multiple Myeloma;   Myelofibrosis;   Anemia, Aplastic;   Hemoglobinuria, Paroxysmal
Intervention:   Drug: Basiliximab
Sponsor:   Indiana University School of Medicine
Recruiting - verified March 2010

Condition:   Hyperparathyroidism, Primary
Interventions:   Drug: Placebo;   Drug: cinacalcet HCl
Sponsor:   Amgen
Not yet recruiting - verified March 2010

Condition:   Severe Nodular Acne
Intervention:   Drug: CIP-Isotretinoin and Isotretinoin
Sponsor:   Cipher Pharmaceuticals Inc.
Recruiting - verified February 2010

Condition:   Gastroesophageal Reflux
Interventions:   Drug: Rabeprazole sodium capsules;   Drug: placebo;   Drug: Rabeprazole sodium capsules
Sponsors:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.;   Eisai Inc.
Recruiting - verified February 2010

Conditions:   Diabetes Mellitus, Type 2;   Acute Coronary Syndrome
Interventions:   Drug: Alogliptin;   Drug: Placebo
Sponsor:   Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010

Condition:   Attention Deficit Hyperactivity Disorder
Intervention:   Drug: LY2216684
Sponsor:   Eli Lilly and Company
Recruiting - verified March 2010

Condition:   Dyslipidemia
Interventions:   Drug: ER niacin (+) laropiprant (ERN/LRPT);   Drug: Comparator: ER niacin (+) laropiprant (ERN/LRPT);   Drug: Comparator: Extended-release niacin (ERN);   Drug: Comparator: Placebo to ERN/LRPT
Sponsor:   Merck
Recruiting - verified March 2010

Condition:   Type 2 Diabetes
Interventions:   Drug: Saxagliptin;   Drug: Metformin XR;   Drug: Metformin XR
Sponsors:   AstraZeneca;   Bristol-Myers Squibb
Recruiting - verified February 2010

Condition:   Leukemia
Interventions:   Genetic: DNA analysis;   Genetic: RNA analysis;   Genetic: cytogenetic analysis;   Genetic: fluorescence in situ hybridization;   Genetic: gene expression analysis;   Genetic: microarray analysis;   Genetic: mutation analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: flow cytometry;   Other: laboratory biomarker analysis;   Other: pharmacological study
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Seasonal Influenza;   Cough;   Sore Throat;   Nasal Congestion;   Myalgia;   Headache;   Fatigue
Interventions:   Drug: Peramivir;   Drug: Peramivir
Sponsors:   BioCryst Pharmaceuticals;   Department of Health and Human Services
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Drug: carboplatin;   Drug: ifosfamide;   Drug: paclitaxel
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Advanced Non-Small Cell Lung Cancer
Interventions:   Drug: Pemetrexed;   Drug: Carboplatin;   Drug: Paclitaxel;   Biological: Bevacizumab
Sponsor:   Eli Lilly and Company
Recruiting - verified March 2010

Conditions:   Bladder Cancer;   Prostate Cancer;   Transitional Cell Cancer of the Renal Pelvis and Ureter;   Urethral Cancer
Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: gemcitabine hydrochloride;   Drug: placebo administration
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Alzheimer's Disease
Interventions:   Drug: Placebo;   Drug: ABT-126;   Drug: donepezil
Sponsor:   Abbott
Recruiting - verified January 2010

Conditions:   Disease, Hodgkin;   Lymphoma, Large-Cell, Anaplastic;   Lymphoma, Non-Hodgkin
Intervention:   Drug: SGN-35
Sponsor:   Seattle Genetics, Inc.
Recruiting - verified February 2010

Condition:   Endometrial Cancer
Interventions:   Drug: carboplatin;   Drug: cisplatin;   Drug: paclitaxel
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Kidney Cancer;   Nonneoplastic Condition
Interventions:   Biological: dactinomycin;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: vincristine sulfate;   Procedure: adjuvant therapy;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Intervention:  
Sponsors:   Memorial Sloan-Kettering Cancer Center;   University of Chicago;   Dana-Farber Cancer Institute;   Georgetown University;   Johns Hopkins University;   M.D. Anderson Cancer Center;   University of Alabama at Birmingham;   University of California, San Francisco;   University of North Carolina;   Duke University;   Vanderbilt-Ingram Cancer Center;   The Indiana University Simon Cancer Center;   Mayo Clinic;   University of Pittsburgh;   University of Michigan Health System
Recruiting - verified March 2010

Condition:   Asthma
Interventions:   Drug: QMF149 Twisthaler®;   Drug: Mometasone Twisthaler®
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified March 2010

Conditions:   Brain and Central Nervous System Tumors;   Lymphoma;   Neuroblastoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Drug: MET tyrosine kinase inhibitor PF-02341066;   Other: pharmacogenomic studies;   Other: pharmacological study
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Solid Tumors;   Cancer
Interventions:   Drug: XL184;   Drug: Placebo;   Drug: XL184
Sponsor:   Exelixis
Recruiting - verified February 2010

Condition:   Macular Edema Secondary to Central Retinal Vein Occlusion
Interventions:   Biological: VEGF Trap-Eye 2.0mg;   Drug: Sham
Sponsors:   Regeneron Pharmaceuticals;   Bayer
Recruiting - verified February 2010

Condition:   Prostate Cancer
Interventions:   Drug: bicalutamide;   Drug: buserelin;   Drug: flutamide;   Drug: goserelin;   Drug: leuprolide acetate;   Drug: triptorelin;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Lymphoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Drug: dexrazoxane hydrochloride;   Drug: doxorubicin hydrochloride;   Drug: obatoclax mesylate;   Drug: vincristine sulfate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Heart Failure
Intervention:  
Sponsor:   Medtronic Cardiac Rhythm Disease Management
Recruiting - verified March 2010

Condition:   Attention Deficit Disorder With Hyperactivity
Interventions:   Drug: Placebo;   Drug: OROS MPH
Sponsor:   Ortho-McNeil Janssen Scientific Affairs, LLC
Recruiting - verified February 2010

Condition:   Alzheimer's Disease
Interventions:   Drug: PF-04447943;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified March 2010

Conditions:   Brain and Central Nervous System Tumors;   Sarcoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Drug: pazopanib hydrochloride;   Other: pharmacological study
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chordoma;   Desmoid Tumor;   Sarcoma
Interventions:   Genetic: reverse transcriptase-polymerase chain reaction;   Other: biologic sample preservation procedure;   Other: laboratory biomarker analysis
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Attention Deficit Hyperactivity Disorder
Interventions:   Drug: LY2216684;   Drug: Methylphenidate;   Drug: Placebo (tablet);   Drug: Placebo (capsule)
Sponsor:   Eli Lilly and Company
Recruiting - verified March 2010

Condition:   Factor X Deficiency
Intervention:   Biological: Human Coagulation FACTOR X
Sponsor:   Bio Products Laboratory
Recruiting - verified March 2010

Condition:   Advanced Solid Tumors
Intervention:   Drug: Amrubicin
Sponsor:   Celgene Corporation
Recruiting - verified March 2010

Conditions:   Atrial Fibrillation;   Arrhythmia;   Stroke Prevention;   Mortality
Interventions:   Device: Left atrial ablation;   Drug: Rate or Rhythm Control Therapy
Sponsors:   Mayo Clinic;   National Heart, Lung, and Blood Institute (NHLBI);   Duke University;   St. Jude Medical;   Biosense Webster, Inc.
Recruiting - verified February 2010

Condition:   Ovarian Neoplasms
Interventions:   Biological: IMC-3G3;   Drug: liposomal doxorubicin
Sponsor:   ImClone LLC
Recruiting - verified February 2010

Condition:   Alzheimer Disease
Interventions:   Drug: Dimebon 20 mg po TID;   Drug: Placebo po TID
Sponsors:   Pfizer;   Medivation, Inc.
Recruiting - verified March 2010

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Placebo;   Drug: GW856553;   Drug: GW856553
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Neuroblastoma
Interventions:   Genetic: loss of heterozygosity analysis;   Other: cytology specimen collection procedure;   Procedure: biopsy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Fracture Healing
Interventions:   Drug: AMG 785 70mg;   Drug: AMG 785 210mg;   Drug: AMG 785 140 mg;   Drug: Placebo
Sponsor:   Amgen
Recruiting - verified March 2010

Condition:   Alzheimer's Disease
Interventions:   Drug: LY2062430;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting - verified March 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Intervention:   Other: laboratory biomarker analysis
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Kidney Cancer;   Nonneoplastic Condition
Interventions:   Genetic: loss of heterozygosity analysis;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: immunohistochemistry staining method;   Procedure: computed tomography;   Procedure: magnetic resonance imaging
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Lymphoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lymphoma
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Neoplasm of Uncertain Malignant Potential;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention:   Other: cytology specimen collection procedure
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Other: biologic sample preservation procedure;   Other: medical chart review
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Dyslipidaemia
Interventions:   Drug: Niaspan;   Drug: GSK256073;   Drug: GSK256073;   Drug: GSK256073;   Drug: Placebo;   Drug: GSK256073;   Drug: GSK256073
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Conditions:   Herpes Zoster;   Shingles
Interventions:   Drug: valacyclovir;   Drug: FV-100;   Drug: FV-100;   Drug: Valacyclovir placebo;   Drug: FV-100 placebo
Sponsor:   Inhibitex
Recruiting - verified February 2010

Condition:   Head and Neck Cancer
Interventions:   Other: biologic sample preservation procedure;   Procedure: biopsy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Cancer
Intervention:   Other: biologic sample preservation procedure
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Prostate Cancer
Intervention:   Drug: Sipuleucel-T
Sponsor:   Dendreon
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Other: clinical observation;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Fragile X Syndrome
Intervention:   Drug: Riluzole
Sponsors:   Indiana University;   Indiana Clinical and Translational Science Institure (I-CTSI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: bevacizumab;   Drug: docetaxel;   Drug: doxorubicin;   Drug: cyclophosphamide;   Drug: cyclophosphamide;   Drug: pegfilgrastim
Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   Genentech;   US Oncology Research
Recruiting - verified March 2010

Condition:   Alzheimer's Disease
Interventions:   Drug: BMS-708163;   Drug: Placebo
Sponsor:   Bristol-Myers Squibb
Recruiting - verified December 2009

Condition:   Solid Organ Malignancy
Interventions:   Drug: Amrubicin;   Drug: Cyclophosphamide
Sponsors:   Hoosier Oncology Group;   Celgene Corporation
Recruiting - verified February 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Biological: bevacizumab;   Drug: temozolomide;   Other: placebo
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Endometrial Cancer
Interventions:   Drug: Ixabepilone;   Drug: Doxorubicin;   Drug: Paclitaxel
Sponsor:   Bristol-Myers Squibb
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: systemic chemotherapy;   Procedure: axillary lymph node dissection;   Procedure: neoadjuvant therapy;   Procedure: sentinel lymph node biopsy;   Procedure: therapeutic conventional surgery;   Procedure: ultrasound imaging
Sponsors:   American College of Surgeons;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Relapsing-Remitting Multiple Sclerosis
Interventions:   Drug: LY2127399;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting - verified March 2010

Condition:   Autism
Interventions:   Drug: CM-AT;   Drug: Placebo
Sponsor:   Curemark
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: eribulin mesylate;   Drug: ixabepilone
Sponsor:   Eisai Inc.
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: neratinib;   Other: placebo
Sponsor:   Wyeth
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: Everolimus;   Drug: Placebo
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified February 2010

Condition:   Myocardial Infarction
Interventions:   Drug: Prochymal®;   Drug: Placebo
Sponsor:   Osiris Therapeutics
Recruiting - verified March 2010

Conditions:   Leukemia;   Lymphoma
Interventions:   Biological: filgrastim;   Drug: asparaginase;   Drug: bortezomib;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Coronary Artery Bypass;   Myocardial Infarction;   Ventricular Dysfunction, Left;   Stroke;   Cardiopulmonary Bypass
Interventions:   Drug: Acadesine;   Drug: Normal Saline
Sponsor:   Schering-Plough
Recruiting - verified March 2010

Conditions:   Breast Cancer;   Metastatic Cancer;   Multiple Myeloma and Plasma Cell Neoplasm;   Musculoskeletal Complications;   Pain;   Prostate Cancer;   Urinary Complications
Intervention:   Drug: zoledronic acid
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: arsenic trioxide;   Drug: cytarabine;   Drug: idarubicin;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: mitoxantrone hydrochloride;   Drug: tretinoin;   Genetic: cytogenetic analysis;   Genetic: polymerase chain reaction;   Other: laboratory biomarker analysis
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Advanced Solid Malignancies
Intervention:   Drug: REGN421
Sponsors:   Regeneron Pharmaceuticals;   Sanofi-Aventis
Recruiting - verified February 2010

Condition:   Heart Failure
Intervention:  
Sponsor:   Medtronic Cardiac Rhythm Disease Management
Recruiting - verified February 2010

Condition:   Anterior Ischemic Optic Neuropathy
Intervention:   Drug: Diagnostic procedures
Sponsor:   Bayer
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: Everolimus, Exemestane;   Drug: Placebo, Exemestane
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified March 2010

Condition:   Malignant Melanoma
Interventions:   Drug: ABI-007;   Drug: Dacarbazine
Sponsors:   Abraxis BioScience Inc.;   University of Arizona
Recruiting - verified August 2009

Conditions:   Leukemia, Myeloid, Acute;   Acute Lymphoblastic Leukemia;   Myelodysplasia;   Leukemia, Myelogenous, Chronic;   Lymphoma, Non-Hodgkin
Intervention:   Drug: Sitagliptin
Sponsor:   Indiana University School of Medicine
Recruiting - verified March 2010

Condition:   Prostate Cancer
Interventions:   Drug: Dasatinib;   Drug: Leuprolide Acetate (LHRH Analogue);   Procedure: Radical Prostatectomy
Sponsors:   Hoosier Oncology Group;   Bristol-Myers Squibb
Recruiting - verified February 2010

Conditions:   Non-small Cell Lung Cancer;   Anemia;   Cancer;   Lung Cancer
Interventions:   Drug: darbepoetin alfa 500 mcg Q3W;   Drug: placebo
Sponsor:   Amgen
Recruiting - verified March 2010

Conditions:   Insomnia;   Attention Deficit Hyperactivity Disorder
Intervention:   Drug: eszopiclone
Sponsor:   Sepracor, Inc.
Recruiting - verified February 2010

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Alogliptin and metformin;   Drug: Alogliptin and metformin;   Drug: Glipizide and metformin
Sponsor:   Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010

Condition:   Arthritis, Rheumatoid
Interventions:   Drug: CP-690,550;   Drug: CP-690,550;   Drug: Placebo;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Hypertension
Interventions:   Drug: TAK-491 and chlorthalidone;   Drug: TAK-491 and chlorthalidone;   Drug: TAK-491 and chlorthalidone;   Drug: TAK-491 and chlorthalidone;   Drug: TAK-491 and chlorthalidone;   Drug: TAK-491 and chlorthalidone;   Drug: Chlorthalidone;   Drug: Chlorthalidone;   Drug: TAK-491;   Drug: TAK-491;   Drug: TAK-491
Sponsor:   Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010

Condition:   Systemic Sclerosis
Intervention:   Drug: treprostinil diethanolamine
Sponsor:   United Therapeutics
Not yet recruiting - verified February 2009

Condition:   Metastatic Pancreatic Cancer
Interventions:   Drug: ABI-007/Gemcitabine;   Drug: Gemcitabine
Sponsor:   Abraxis BioScience Inc.
Recruiting - verified December 2009

Condition:   Ovarian Cancer
Interventions:   Drug: MORAb-003 (farletuzumab);   Drug: MORAb-003 (farletuzumab);   Drug: 0.9% Saline
Sponsor:   Morphotek
Recruiting - verified October 2009

Condition:   Haemophilia A
Interventions:   Drug: recombinant factor VIII (N8);   Procedure: Blood drawn for laboratory testing
Sponsor:   Novo Nordisk
Recruiting - verified March 2010

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Apixaban;   Drug: Placebo
Sponsors:   Bristol-Myers Squibb;   Pfizer;   Duke University
Recruiting - verified October 2009

Condition:   Carcinoma, Renal Cell
Interventions:   Drug: axitinib;   Drug: axitinib;   Drug: axitinib
Sponsor:   Pfizer
Recruiting - verified March 2010

Conditions:   Adrenocortical Carcinoma;   Kidney Cancer;   Liver Cancer;   Neuroblastoma;   Retinoblastoma;   Sarcoma
Interventions:   Biological: cixutumumab;   Other: laboratory biomarker analysis
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Chronic Kidney Disease;   Iron-Deficiency Anemia
Interventions:   Drug: IV Iron;   Drug: Ferrous Sulfate
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified March 2010

Conditions:   Endometrial Cancer;   Fatigue;   Neurotoxicity
Interventions:   Drug: carboplatin;   Drug: paclitaxel;   Radiation: brachytherapy;   Radiation: intensity-modulated radiation therapy;   Radiation: radiation therapy
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Acute Coronary Syndrome;   Myocardial Infarction;   Myocardial Ischemia;   Unstable Angina
Intervention:   Drug: Rivaroxaban; Placebo
Sponsors:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.;   Bayer
Recruiting - verified February 2010

Condition:   Carcinoma, Non-Small-Cell Lung
Interventions:   Drug: Pemetrexed;   Drug: Pemetrexed;   Drug: BIBF1120;   Drug: Folic Acid;   Drug: Folic Acid;   Drug: BIBF1120 placebo
Sponsor:   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010

Condition:   Cervical Cancer
Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: paclitaxel;   Drug: topotecan hydrochloride
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Advanced Squamous Non-Small Cell Lung Cancer
Interventions:   Biological: AMG 479;   Biological: AMG 479;   Drug: Carboplatin;   Biological: AMG 479;   Drug: Paclitaxel
Sponsor:   Amgen
Recruiting - verified February 2010

Condition:   Chronic Plaque Psoriasis
Intervention:   Biological: HUMIRA® (adalimumab)
Sponsor:   Abbott
Recruiting - verified January 2010

Conditions:   Atherosclerosis;   Cardiovascular Disease;   Coronary Heart Disease;   CV Risk
Interventions:   Drug: Darapladib;   Drug: Placebo
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Solid Tumors
Intervention:   Drug: Sunitinib
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Diffuse Large B-cell Lymphoma
Interventions:   Drug: RAD001;   Drug: Placebo
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: bevacizumab;   Drug: ixabepilone;   Drug: paclitaxel;   Drug: paclitaxel albumin-stabilized nanoparticle formulation
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Colon Cancer;   Colorectal Cancer;   Rectal Cancer;   Metastatic Colorectal Cancer
Interventions:   Drug: Panitumumab;   Drug: Bevacizumab;   Drug: mFOLFOX6
Sponsor:   Amgen
Recruiting - verified March 2010

Condition:   Crohn's Disease
Interventions:   Drug: vedolizumab;   Other: Placebo
Sponsor:   Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2010

Condition:   Mental Disorder
Intervention:   Behavioral: Adding a Consumer Provider to Intensive Case Management Teams (called MHICM in the VA)
Sponsor:   Department of Veterans Affairs
Recruiting - verified March 2010

Conditions:   Carcinoma;   Neuroendocrine Tumors
Intervention:   Biological: A12
Sponsor:   ImClone LLC
Recruiting - verified February 2010

Conditions:   Advanced Breast Cancer;   Breast Cancer
Interventions:   Drug: Neratinib;   Drug: Lapatinib plus Capecitabine
Sponsor:   Wyeth
Recruiting - verified February 2010

Conditions:   Phenylketonuria;   Hyperphenylalaninaemia
Intervention:   Drug: Sapropterin Dihydrochloride
Sponsor:   BioMarin Pharmaceutical
Recruiting - verified January 2010

Conditions:   Systemic Sclerosis;   Scleroderma
Interventions:   Drug: treprostinil diethanolamine;   Drug: placebo
Sponsor:   United Therapeutics
Recruiting - verified February 2010

Condition:   Breast Cancer
Interventions:   Biological: trastuzumab;   Radiation: radiation therapy
Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Brain and Central Nervous System Tumors;   Chemotherapeutic Agent Toxicity;   Cognitive/Functional Effects;   Neurotoxicity;   Psychosocial Effects of Cancer and Its Treatment;   Radiation Toxicity;   Therapy-related Toxicity
Interventions:   Other: questionnaire administration;   Procedure: cognitive assessment;   Procedure: psychosocial assessment and care;   Procedure: quality-of-life assessment
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Chronic Migraine
Interventions:   Drug: propranolol LA;   Drug: topiramate;   Drug: placebo
Sponsors:   The EMMES Corporation;   National Institute of Neurological Disorders and Stroke (NINDS);   Ortho-McNeil Janssen Scientific Affairs, LLC;   CRC Operations Center
Recruiting - verified March 2010

Condition:   Melanoma
Interventions:   Biological: OncoVEXGM-CSF;   Biological: GM-CSF
Sponsor:   BioVex Limited
Recruiting - verified March 2010

Condition:   Hip Replacement, Total
Intervention:   Drug: Ceftobiprole
Sponsor:   Ortho-McNeil Janssen Scientific Affairs, LLC
Recruiting - verified February 2010

Condition:   Crohn's Disease
Intervention:   Drug: Ustekinumab; CNTO1275
Sponsor:   Centocor, Inc.
Recruiting - verified March 2010

Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndromes;   Lymphoma;   Multiple Myeloma;   Leukemia, Myelomonocytic, Chronic
Intervention:   Drug: azacitidine
Sponsor:   Celgene Corporation
Recruiting - verified March 2010

Condition:   Pneumonia
Intervention:   Drug: CP-70,429 and PF-03709270
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Neoplasms
Intervention:   Drug: BIBW 2992
Sponsor:   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010

Condition:   Chronic Lymphocytic Leukemia
Interventions:   Drug: ofatumumab (GSK1841157) infusion;   Drug: chlorambucil, tablets
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Drug: cisplatin;   Drug: dexrazoxane hydrochloride;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: zoledronic acid;   Procedure: adjuvant therapy;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: ASA404 in combination with docetaxel;   Drug: Placebo in combination with docetaxel
Sponsor:   Novartis Pharmaceuticals
Recruiting - verified March 2010

Condition:   Diabetes Mellitus
Interventions:   Drug: Exubera;   Other: Randomized diabetes therapy
Sponsor:   Pfizer
Recruiting - verified March 2010

Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Long-term Effects Secondary to Cancer Therapy in Children;   Lymphoma;   Lymphoproliferative Disorder;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Precancerous Condition;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Other: survey administration;   Procedure: assessment of therapy complications;   Procedure: long-term screening;   Procedure: study of high risk factors
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Non-small Cell Lung Cancer
Interventions:   Drug: Pemetrexed;   Radiation: Radiation Therapy
Sponsors:   Hoosier Oncology Group;   Eli Lilly and Company
Recruiting - verified February 2010

Condition:   Colorectal Cancer
Interventions:   Procedure: therapeutic conventional surgery;   Procedure: therapeutic laparoscopic surgery
Sponsors:   American College of Surgeons;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Type 2 Diabetes
Intervention:   Drug: sitagliptin phosphate
Sponsor:   Merck
Recruiting - verified March 2010

Condition:   Glioma
Interventions:   Drug: TMZ;   Drug: BIBW 2992 plus TMZ;   Drug: BIBW 2992
Sponsor:   Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010

Condition:   Endometrial Cancer
Interventions:   Biological: bevacizumab;   Drug: temsirolimus
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Locally Advanced and/or Metastatic Renal Cell Carcinoma
Interventions:   Drug: Sunitinib;   Drug: Pazopanib
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Fibromyalgia
Intervention:   Drug: Treatment for Fibromyalgia
Sponsor:   Eli Lilly and Company
Recruiting - verified March 2010

Condition:   Thymoma and Thymic Carcinoma
Intervention:   Drug: AZD0530
Sponsors:   Indiana University Melvin and Bren Simon Cancer Center;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dasatinib;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: etoposide;   Drug: ifosfamide;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Brain and Central Nervous System Tumors;   Childhood Germ Cell Tumor;   Extragonadal Germ Cell Tumor;   Liver Cancer;   Neuroblastoma;   Ototoxicity;   Ovarian Cancer;   Sarcoma
Interventions:   Drug: sodium thiosulfate;   Procedure: examination
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Prostate Cancer
Interventions:   Biological: Sipuleucel-T;   Biological: Sipuleucel-T;   Biological: Sipuleucel-T
Sponsor:   Dendreon
Recruiting - verified February 2010

Condition:   Patent Ductus Arteriosus
Intervention:   Device: AMPLATZER Duct Occluder II
Sponsor:   AGA Medical Corporation
Recruiting - verified March 2010

Condition:   Huntington's Disease
Interventions:   Drug: Creatine Monohydrate (HD-02);   Drug: placebo
Sponsors:   Massachusetts General Hospital;   University of Rochester;   National Center for Complementary and Alternative Medicine (NCCAM)
Recruiting - verified March 2010

Condition:   Age Related Macular Degeneration
Interventions:   Drug: Lucentis;   Drug: PF-04523655;   Drug: PF-04523655;   Drug: PF-04523655;   Drug: Combination
Sponsors:   Pfizer;   Quark Pharmaceuticals
Recruiting - verified March 2010

Condition:   Melanoma (Skin)
Intervention:   Drug: dasatinib
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Pancreatic Neoplasm
Interventions:   Biological: monoclonal antibody;   Drug: chemotherapy
Sponsors:   Pfizer;   University of Pennsylvania
Recruiting - verified March 2010

Condition:   Transitional Cell Carcinoma of the Bladder
Interventions:   Drug: Dasatinib;   Procedure: Radical Cystectomy
Sponsors:   Hoosier Oncology Group;   Bristol-Myers Squibb
Recruiting - verified February 2010

Condition:   Thyroid Cancer
Interventions:   Drug: XL184;   Drug: Placebo
Sponsor:   Exelixis
Recruiting - verified March 2010

Conditions:   Diabetic Retinopathy;   Diabetes Complications
Interventions:   Procedure: Laser Treatment;   Drug: PF-04523655 high;   Drug: PF-04523655 middle;   Drug: PF-04523655 low
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Clopidogrel;   Drug: Prasugrel;   Drug: Commercially-available Aspirin
Sponsors:   Eli Lilly and Company;   Daiichi Sankyo Co., Ltd.;   Duke University
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Drug: sunitinib malate;   Other: placebo
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Carcinoma, Hepatocellular
Interventions:   Drug: Nexavar (Sorafenib, BAY43-9006);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified March 2010

Condition:   Retinoblastoma
Interventions:   Genetic: DNA ploidy analysis;   Genetic: DNA stability analysis;   Genetic: Southern blotting;   Genetic: genetic linkage analysis;   Genetic: loss of heterozygosity analysis;   Genetic: mutation analysis;   Genetic: polymorphism analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: questionnaire administration;   Other: study of socioeconomic and demographic variables;   Procedure: evaluation of cancer risk factors;   Procedure: mutation carrier screening
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Kidney Neoplasms
Interventions:   Drug: Axitinib (AG-013736);   Drug: Sorafenib
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Intervention:   Drug: cilengitide
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Prostatic Neoplasms
Interventions:   Drug: Prednisone;   Drug: sunitinib;   Drug: Placebo;   Drug: Prednisone
Sponsor:   Pfizer
Recruiting - verified March 2010

Conditions:   Prevention of Venous Thromboembolism;   Cancer
Interventions:   Drug: AVE5026;   Drug: Placebo
Sponsor:   Sanofi-Aventis
Recruiting - verified March 2010

Conditions:   Kidney Cancer;   Leukemia;   Sarcoma;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions:   Biological: dactinomycin;   Drug: vincristine sulfate;   Genetic: polymerase chain reaction;   Genetic: polymorphism analysis;   Other: liquid chromatography;   Other: mass spectrometry;   Other: pharmacological study
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Multiple Sclerosis
Interventions:   Drug: Teriflunomide (HMR1726);   Drug: Placebo
Sponsor:   Sanofi-Aventis
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: SC-PEG E. coli L-asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: bortezomib;   Drug: cytarabine;   Drug: etoposide phosphate;   Drug: idarubicin
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Hyperglycemia;   Obesity;   Diabetes Mellitus
Interventions:   Behavioral: Registered Dietitian Counseling Alone;   Behavioral: Registered Dietitian Counseling Plus YMCA Group Lifestyle Intervention
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified March 2010

Conditions:   Breast Cancer;   Cognitive/Functional Effects;   Fatigue;   Psychosocial Effects of Cancer and Its Treatment;   Sleep Disorders
Interventions:   Procedure: assessment of therapy complications;   Procedure: cognitive assessment;   Procedure: fatigue assessment and management;   Procedure: psychosocial assessment and care
Sponsors:   International Breast Cancer Study Group;   National Cancer Institute (NCI);   Australian New Zealand Breast Cancer Trials Group;   Cancer and Leukemia Group B
Recruiting - verified March 2010

Condition:   Esophageal Cancer
Interventions:   Biological: cetuximab;   Drug: cisplatin;   Drug: paclitaxel;   Radiation: radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Intervention:   Device: Third Eye Retroscope Auxiliary Imaging System
Sponsors:   M.D. Anderson Cancer Center;   Avantis Medical Systems
Recruiting - verified March 2010

Condition:   Coronary Heart Disease
Interventions:   Drug: dalcetrapib;   Drug: Placebo;   Drug: Evidence-based medical care for Acute Coronary Syndrome
Sponsor:   Hoffmann-La Roche
Recruiting - verified March 2010

Condition:   Atrial Septal Defect
Intervention:   Device: AMPLATZER Septal Occluder
Sponsor:   AGA Medical Corporation
Recruiting - verified January 2009

Condition:   Fatty Liver Disease
Intervention:   Drug: Exenatide
Sponsors:   Indiana University;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified February 2010

Condition:   Ventricular Septal Defects
Intervention:   Device: Muscular VSD Occluder device implantation (AMPLATZER Muscular VSD Occluder)
Sponsor:   AGA Medical Corporation
Recruiting - verified October 2009

Condition:   Lung Cancer
Interventions:   Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group
Recruiting - verified March 2010

Condition:   Hepatic Veno-Occlusive Disease
Intervention:   Drug: Defibrotide
Sponsor:   Gentium SpA
Recruiting - verified February 2010

Condition:   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention:   Biological: aflibercept
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Multiple Sclerosis
Interventions:   Drug: Teriflunomide (HMR1726);   Drug: Placebo
Sponsor:   Sanofi-Aventis
Recruiting - verified March 2010

Condition:   Small Cell Lung Cancer
Interventions:   Drug: Cisplatin;   Drug: Etoposide;   Drug: Placebo;   Drug: Cisplatin;   Drug: Etoposide;   Drug: ZD6474
Sponsors:   Hoosier Oncology Group;   AstraZeneca
Recruiting - verified February 2010

Condition:   Hemophilia A
Interventions:   Drug: Recombinant Anti-hemophilic Factor VIII (Kogenate®FS);   Drug: Recombinant Anti-hemophilic Factor VIII (Kogenate®FS)
Sponsor:   Bayer
Recruiting - verified March 2010

Conditions:   Attention Deficit Hyperactivity Disorder;   Dyslexia
Interventions:   Drug: Atomoxetine;   Drug: Placebo
Sponsor:   Eli Lilly and Company
Recruiting - verified March 2010

Condition:   Infrarenal Abdominal Aortic Aneurysm
Intervention:   Device: Anaconda Stent Graft System
Sponsors:   Terumo CVS;   Vascutek Ltd., Scotland
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: bevacizumab;   Drug: letrozole;   Drug: tamoxifen citrate;   Other: placebo
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplasia;   Chronic Myeloid Leukemia
Interventions:   Radiation: Total Body Irradiation;   Drug: Thiotepa;   Drug: Fludarabine;   Biological: Rabbit ATG;   Drug: Palifermin
Sponsor:   Indiana University
Recruiting - verified January 2010

Condition:   Head and Neck Cancer
Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: docetaxel;   Drug: fluorouracil
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Tumors
Intervention:   Drug: Trabectedin; ET 743; Yondelis
Sponsors:   Johnson & Johnson Pharmaceutical Research & Development, L.L.C.;   PharmaMar S.A.
Recruiting - verified February 2010

Conditions:   Hemodialysis;   Hypertension;   Left Ventricular Hypertrophy
Interventions:   Drug: Lisinopril;   Drug: Atenolol
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Recruiting - verified March 2010

Conditions:   Esophageal Cancer;   Adenocarcinoma of the Esophagus;   Squamous Cell Carcinoma
Interventions:   Drug: OncoGel (Paclitaxel gel);   Drug: cisplatin;   Drug: 5-FU;   Radiation: radiation therapy;   Procedure: esophageal resection
Sponsor:   Protherics
Recruiting - verified March 2010

Conditions:   Cognitive/Functional Effects;   Metastatic Cancer;   Neurotoxicity;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions:   Drug: memantine hydrochloride;   Other: placebo;   Radiation: radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Prostate Cancer
Interventions:   Drug: bicalutamide;   Drug: flutamide;   Radiation: radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B
Recruiting - verified March 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: docetaxel;   Drug: paclitaxel
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Metastatic Breast Cancer
Interventions:   Drug: docetaxel;   Drug: pertuzumab;   Drug: placebo;   Drug: trastuzumab
Sponsors:   Genentech;   Roche Pharma AG
Recruiting - verified March 2010

Condition:   Alzheimer's Disease
Interventions:   Drug: PF-04494700;   Drug: PF-04494700;   Drug: Placebo
Sponsors:   Pfizer;   Alzheimer's Disease Cooperative Study (ADCS)
Recruiting - verified March 2010

Conditions:   Colorectal Neoplasms;   Neoplasm Metastasis
Interventions:   Drug: Aflibercept (AVE0005);   Drug: Placebo
Sponsors:   Sanofi-Aventis;   Regeneron Pharmaceuticals;   National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: etoposide;   Drug: lestaurtinib;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Kidney Disease;   Nephropathy;   Type 2 Diabetes
Interventions:   Drug: losartan;   Drug: lisinopril;   Drug: losartan
Sponsor:   Department of Veterans Affairs
Recruiting - verified March 2010

Condition:   Retinoblastoma
Interventions:   Biological: filgrastim;   Drug: carboplatin;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: thiotepa;   Drug: vincristine sulfate;   Procedure: autologous bone marrow transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: tacrolimus;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: allogeneic bone marrow transplantation
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Focal Segmental Glomerulosclerosis (FSGS)
Intervention:   Drug: rituximab
Sponsors:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK);   Genentech
Recruiting - verified March 2010

Condition:   Autism
Intervention:   Drug: Paliperidone ER
Sponsors:   Indiana University School of Medicine;   Ortho-McNeil Janssen Scientific Affairs, LLC
Recruiting - verified March 2010

Conditions:   Breast Cancer;   Carcinoma of the Breast
Interventions:   Drug: Paclitaxel;   Drug: Trastuzumab
Sponsors:   Dana-Farber Cancer Institute;   Brigham and Women's Hospital;   Beth Israel Deaconess Medical Center;   Massachusetts General Hospital;   Genentech
Recruiting - verified March 2010

Condition:   Leukemia
Intervention:   Drug: asparaginase-Erwinia
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Lung Cancer;   Radiation Toxicity
Interventions:   Biological: cetuximab;   Drug: carboplatin;   Drug: paclitaxel;   Radiation: 3-dimensional conformal radiation therapy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   Cancer and Leukemia Group B
Recruiting - verified March 2010

Condition:   Cancer
Interventions:   Drug: TAK-285 Dose Escalation Cohorts;   Drug: TAK-285 Recommended Phase 2 Dosing Cohort
Sponsor:   Millennium Pharmaceuticals, Inc.
Recruiting - verified March 2010

Conditions:   Atherosclerosis;   Myocardial Ischemia;   Myocardial Infarction
Interventions:   Drug: SCH 530348;   Drug: Placebo
Sponsors:   Schering-Plough;   Duke University
Recruiting - verified March 2010

Condition:   Epilepsy
Interventions:   Drug: lacosamide;   Drug: lacosamide
Sponsor:   UCB, Inc.
Recruiting - verified March 2010

Conditions:   Staphylococcus Aureus;   Bacteremia;   Mediastinitis
Interventions:   Biological: V710;   Biological: Comparator: Placebo (unspecified)
Sponsor:   Merck
Recruiting - verified March 2010

Condition:   Multiple Myeloma
Interventions:   Drug: bortezomib, thalidomide, and dexamethasone (VTD);   Drug: bortezomib and dexamethasone (VD);   Drug: bortezomib, melphalan and prednisone (VMP)
Sponsor:   Millennium Pharmaceuticals, Inc.
Recruiting - verified February 2010

Conditions:   Psoriasis;   Arthritis, Psoriatic
Interventions:   Drug: conventional systemic agents;   Biological: infliximab;   Biological: ustekinumab;   Biological: Biological therapies other than infliximab and ustekinumab
Sponsor:   Centocor Ortho Biotech Services, L.L.C.
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Procedure: therapeutic thoracoscopy;   Procedure: videothoracoscopy
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   American College of Surgeons;   Southwest Oncology Group
Recruiting - verified March 2010

Conditions:   Sepsis;   Severe Sepsis;   Septic Shock
Interventions:   Procedure: Early Goal Directed Therapy (EGDT);   Procedure: Protocolized Standard Care (PSC);   Procedure: Usual Care (UC)
Sponsors:   National Institute of General Medical Sciences (NIGMS);   University of Pittsburgh
Recruiting - verified September 2008

Condition:   Neuroblastoma
Interventions:   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: topotecan hydrochloride
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: Trastuzumab;   Drug: Lapatinib
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Endometrial Cancer
Interventions:   Drug: cisplatin;   Radiation: brachytherapy;   Radiation: radiation therapy
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Ulcerative Colitis
Interventions:   Biological: golimumab, placebo;   Biological: Golimumab, placebo;   Biological: Placebo
Sponsors:   Centocor, Inc.;   Schering-Plough
Recruiting - verified February 2010

Condition:   Leukemia
Interventions:   Genetic: DNA ploidy analysis;   Genetic: chromosomal translocation analysis;   Genetic: fluorescence in situ hybridization;   Genetic: polymorphism analysis;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Procedure: biopsy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Tumor Antigen-positive Non-Small Cell Lung Cancer
Interventions:   Biological: GSK1572932A Antigen-Specific Cancer Immunotherapeutic;   Biological: Placebo Control
Sponsor:   GlaxoSmithKline
Recruiting - verified March 2010

Condition:   Heart Decompensation
Interventions:   Drug: Placebo;   Drug: Nesiritide
Sponsor:   Scios, Inc.
Recruiting - verified February 2010

Conditions:   Childhood Germ Cell Tumor;   Extragonadal Germ Cell Tumor;   Ovarian Cancer;   Testicular Germ Cell Tumor
Interventions:   Biological: filgrastim;   Drug: carboplatin;   Drug: ifosfamide;   Drug: paclitaxel
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia, Lymphocytic, Chronic
Intervention:   Drug: alvocidib (HMR1275)
Sponsor:   Sanofi-Aventis
Recruiting - verified March 2010

Conditions:   Ototoxicity;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention:   Procedure: management of therapy complications
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Venous Thrombosis;   Pulmonary Embolism
Interventions:   Drug: Apixaban;   Drug: Enoxaparin
Sponsor:   Bristol-Myers Squibb
Recruiting - verified February 2010

Condition:   Ovarian Cancer
Interventions:   Drug: levonorgestrel;   Other: placebo
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Cognitive/Functional Effects;   Leukemia;   Long-term Effects Secondary to Cancer Therapy in Children;   Neurotoxicity;   Psychosocial Effects of Cancer and Its Treatment
Interventions:   Genetic: microarray analysis;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: cognitive assessment;   Procedure: diffusion tensor imaging;   Procedure: management of therapy complications;   Procedure: psychosocial assessment and care
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: bevacizumab;   Drug: cyclophosphamide;   Drug: paclitaxel;   Drug: pegylated liposomal doxorubicin hydrochloride;   Other: placebo
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   Cancer and Leukemia Group B
Recruiting - verified March 2010

Condition:   Thoracic Aortic Aneurysms
Intervention:   Device: Relay Thoracic Stent-Graft
Sponsor:   Bolton Medical
Recruiting - verified March 2010

Condition:   Pulmonary Arterial Hypertension
Interventions:   Drug: Sildenafil citrate;   Drug: Sildenafil citrate;   Drug: Sildenafil citrate;   Drug: Sildenafil citrate
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: dasatinib;   Genetic: gene expression analysis;   Genetic: mutation analysis;   Other: immunohistochemistry staining method;   Other: immunologic technique;   Other: liquid chromatography;   Other: mass spectrometry;   Other: pharmacological study;   Procedure: biopsy
Sponsors:   Radiation Therapy Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Cancer;   Colon Cancer;   Colorectal Cancer;   Metastatic Cancer;   Rectal Cancer;   Metastatic Colorectal Cancer
Interventions:   Drug: FOLFIRI - Panitumumab;   Drug: FOLFIRI - Bevacizumab
Sponsor:   Amgen
Recruiting - verified February 2010

Conditions:   Atrial Fibrillation;   Atrial Flutter
Interventions:   Drug: warfarin;   Drug: apixaban
Sponsor:   Bristol-Myers Squibb
Recruiting - verified October 2009

Condition:   Arthritis, Rheumatoid
Interventions:   Drug: CP-690,550;   Drug: CP-690,550
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: nelarabine;   Drug: pegaspargase;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Biological: bevacizumab;   Drug: capecitabine;   Drug: cyclophosphamide;   Drug: docetaxel;   Drug: doxorubicin hydrochloride;   Drug: gemcitabine hydrochloride;   Procedure: conventional surgery
Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Neuralgia;   Spinal Cord Injuries
Interventions:   Drug: placebo;   Drug: pregabalin
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Biological: filgrastim;   Drug: carboplatin;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: isotretinoin;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: fulvestrant;   Drug: lapatinib ditosylate;   Other: placebo
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Brain Metastases From Non-small Cell Lung Cancer
Intervention:   Drug: HYCAMTIN, oral capsules
Sponsor:   GlaxoSmithKline
Recruiting - verified February 2010

Condition:   Breast Cancer
Intervention:   Drug: chemotherapy
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Biological: filgrastim;   Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Graft Versus Host Disease;   Leukemia
Interventions:   Drug: methotrexate;   Drug: sirolimus;   Drug: tacrolimus
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Kidney Cancer
Interventions:   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Colorectal Neoplasms;   Melanoma;   Prostatic Neoplasms;   Renal Cell Carcinoma;   Neoplasms
Intervention:   Drug: CP-675,206
Sponsor:   Pfizer
Recruiting - verified February 2010

Condition:   Osteoarthritis
Interventions:   Drug: Celecoxib;   Drug: Any commercially available NSAID with the indication for osteoarthritis
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: asparaginase;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: etoposide;   Drug: gemtuzumab ozogamicin;   Drug: mitoxantrone hydrochloride
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: clofarabine;   Drug: cytarabine;   Drug: methotrexate;   Other: laboratory biomarker analysis
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Myelodysplastic Syndromes
Interventions:   Drug: asparaginase;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: etoposide;   Drug: thioguanine
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Alzheimer's Disease
Interventions:   Drug: raloxifene;   Drug: Placebo
Sponsors:   Stanford University;   National Institute on Aging (NIA);   Indiana University;   Kaiser Permanente;   Southern Illinois University
Recruiting - verified February 2010

Conditions:   Heart Failure;   Anemia;   Cardiovascular Disease;   Ventricular Dysfunction;   Congestive Heart Failure
Interventions:   Drug: Darbepoetin alfa;   Drug: Placebo
Sponsor:   Amgen
Recruiting - verified March 2010

Condition:   Kidney Cancer
Intervention:   Biological: aflibercept
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: irinotecan hydrochloride;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Kidney Cancer
Interventions:   Biological: dactinomycin;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   HIV-1
Intervention:   Drug: TMC125
Sponsor:   Tibotec Pharmaceuticals, Ireland
Recruiting - verified February 2010

Conditions:   Arthritis, Rheumatoid;   Osteoarthritis
Interventions:   Drug: celecoxib;   Drug: Ibuprofen;   Drug: Naproxen
Sponsors:   Pfizer;   The Cleveland Clinic
Recruiting - verified March 2010

Conditions:   Amyotrophic Lateral Sclerosis;   ALS
Interventions:   Drug: ceftriaxone;   Other: placebo
Sponsors:   Massachusetts General Hospital;   National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified March 2010

Conditions:   Childhood Malignant Fibrous Histiocytoma of Bone;   Sarcoma
Interventions:   Drug: doxorubicin hydrochloride;   Drug: ifosfamide;   Other: clinical observation;   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Leukemia;   Unspecified Childhood Solid Tumor, Protocol Specific
Intervention:   Drug: sorafenib tosylate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Kidney Cancer
Interventions:   Biological: dactinomycin;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: irinotecan hydrochloride;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: carboplatin;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: thiotepa;   Drug: vincristine sulfate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Retinoblastoma
Interventions:   Drug: carboplatin;   Drug: etoposide;   Drug: vincristine sulfate;   Other: clinical observation
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Non Hodgkin Lymphoma
Interventions:   Drug: enzastaurin;   Drug: placebo
Sponsor:   Eli Lilly and Company
Recruiting - verified March 2010

Condition:   Kidney Cancer
Interventions:   Drug: sorafenib tosylate;   Drug: sunitinib malate;   Other: placebo
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   Southwest Oncology Group;   NCIC Clinical Trials Group
Recruiting - verified March 2010

Condition:   Lung Cancer
Interventions:   Biological: bevacizumab;   Drug: cisplatin;   Drug: docetaxel;   Drug: gemcitabine hydrochloride;   Drug: pemetrexed disodium;   Drug: vinorelbine ditartrate
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Southwest Oncology Group;   Cancer and Leukemia Group B;   NCIC Clinical Trials Group;   North Central Cancer Treatment Group
Recruiting - verified March 2010

Condition:   Anal Cancer
Interventions:   Biological: cetuximab;   Drug: cisplatin;   Drug: fluorouracil;   Radiation: radiation therapy
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: anastrozole;   Drug: chemotherapy;   Drug: exemestane;   Drug: letrozole;   Drug: tamoxifen citrate
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI);   Southwest Oncology Group;   Cancer and Leukemia Group B;   American College of Surgeons;   North Central Cancer Treatment Group;   NCIC Clinical Trials Group;   National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified March 2010

Condition:   Prostate Cancer
Interventions:   Drug: antiandrogen therapy;   Drug: docetaxel
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Kidney Cancer;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Neuroblastoma;   Pulmonary Complications;   Sarcoma
Interventions:   Biological: etanercept;   Drug: methylprednisolone
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Hereditary Breast/Ovarian Cancer (brca1, brca2);   Osteoporosis;   Ovarian Cancer
Interventions:   Drug: zoledronic acid;   Other: clinical observation
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Adrenocortical Carcinoma
Interventions:   Biological: filgrastim;   Biological: pegfilgrastim;   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: mitotane;   Procedure: conventional surgery
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Head and Neck Cancer;   Radiation Toxicity
Interventions:   Drug: amifostine trihydrate;   Drug: cisplatin;   Drug: fluorouracil;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Arrhythmia;   Bradycardia;   Heart Failure;   Sinus Tachycardia
Intervention:  
Sponsor:   Medtronic Cardiac Rhythm Disease Management
Recruiting - verified February 2010

Condition:   Leukemia
Interventions:   Behavioral: compliance monitoring;   Drug: mercaptopurine;   Drug: methotrexate;   Other: study of socioeconomic and demographic variables
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Biological: cetuximab;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium;   Drug: oxaliplatin
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Southwest Oncology Group
Recruiting - verified March 2010

Condition:   Breast Neoplasms
Interventions:   Drug: SU011248;   Drug: Chemotherapy
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Intervention:   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Procedure: Biopsy;   Procedure: Serum Collection;   Procedure: Urine Collection;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Capecitabine;   Drug: Vinorelbine;   Drug: Gemcitabine
Sponsors:   Hoosier Oncology Group;   Department of Defense;   Indiana University School of Medicine;   Walther Cancer Institute
Recruiting - verified February 2010

Condition:   Heart Failure
Interventions:   Drug: Eplerenone;   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Drug: fluorouracil;   Drug: leucovorin calcium;   Drug: oxaliplatin;   Other: clinical observation
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Metastatic Cancer;   Prostate Cancer
Interventions:   Drug: atrasentan hydrochloride;   Drug: docetaxel;   Drug: prednisone;   Other: placebo
Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: PEG-interferon alfa-2b;   Drug: cisplatin;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: methotrexate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   University College London Hospitals
Recruiting - verified March 2010

Condition:   Breast Cancer
Intervention:   Procedure: quality-of-life assessment
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Fallopian Tube Cancer;   Ovarian Cancer;   Peritoneal Cavity Cancer
Interventions:   Drug: paclitaxel;   Drug: paclitaxel poliglumex;   Other: clinical observation
Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Lymphoma
Interventions:   Drug: CHOP regimen;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Conditions:   Carotid Artery Disease;   Carotid Stenosis;   Stroke;   Atherosclerosis
Interventions:   Device: Carotid artery stenting with filter (interventional);   Procedure: Carotid artery endarterectomy (surgical)
Sponsor:   Abbott Vascular
Recruiting - verified March 2010

Condition:   Breast Cancer
Intervention:   Radiation: radiation therapy
Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   Southwest Oncology Group
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Colorectal Cancer
Interventions:   Biological: bevacizumab;   Drug: fluorouracil;   Drug: irinotecan hydrochloride;   Drug: leucovorin calcium
Sponsors:   Eastern Cooperative Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Biological: epratuzumab;   Biological: filgrastim;   Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Non Small Cell Lung Cancer
Interventions:   Drug: Docetaxel;   Biological: cetuximab;   Drug: Pemetrexed
Sponsors:   Eli Lilly and Company;   ImClone LLC
Recruiting - verified March 2010

Condition:   Brain and Central Nervous System Tumors
Interventions:   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: lomustine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Cancer
Interventions:   Genetic: cytogenetic analysis;   Genetic: mutation analysis;   Genetic: polymorphism analysis;   Other: questionnaire administration
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Intervention:   Drug: exemestane
Sponsor:   NCIC Clinical Trials Group
Recruiting - verified March 2010

Conditions:   Metastatic Cancer;   Pain
Intervention:   Radiation: radiation therapy
Sponsors:   NCIC Clinical Trials Group;   National Cancer Institute (NCI);   Radiation Therapy Oncology Group;   Trans Tasman Radiation Oncology Group at Calvary Mater Newcastle
Recruiting - verified March 2010

Conditions:   Metastatic Cancer;   Prostate Cancer
Interventions:   Drug: zoledronic acid;   Other: placebo
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Southwest Oncology Group;   Eastern Cooperative Oncology Group;   NCIC Clinical Trials Group
Recruiting - verified March 2010

Condition:   Lymphoma
Interventions:   Biological: rituximab;   Drug: cisplatin;   Drug: cytarabine;   Drug: dexamethasone;   Drug: gemcitabine hydrochloride;   Other: clinical observation
Sponsor:   NCIC Clinical Trials Group
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: vincristine sulfate;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Leukemia
Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: exemestane;   Drug: tamoxifen citrate;   Drug: triptorelin;   Procedure: oophorectomy;   Radiation: radiation therapy
Sponsors:   International Breast Cancer Study Group;   National Cancer Institute (NCI);   Breast International Group;   Cancer and Leukemia Group B;   NCIC Clinical Trials Group;   North Central Cancer Treatment Group;   National Surgical Adjuvant Breast and Bowel Project (NSABP);   Southwest Oncology Group
Recruiting - verified March 2010

Conditions:   Childhood Germ Cell Tumor;   Extragonadal Germ Cell Tumor;   Ovarian Cancer
Interventions:   Biological: bleomycin sulfate;   Drug: cisplatin;   Drug: etoposide;   Procedure: conventional surgery
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Breast Cancer
Interventions:   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel
Sponsors:   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Neuroblastoma
Interventions:   Biological: therapeutic immune globulin;   Other: clinical observation
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Neuroblastoma
Interventions:   Biological: aldesleukin;   Biological: monoclonal antibody Ch14.18;   Biological: sargramostim;   Drug: isotretinoin
Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
Recruiting - verified March 2010

Condition:   Sarcoma
Interventions:   Biological: dactinomycin;   Drug: busulfan;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: melphalan;   Drug: vincristine sulfate;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: conventional surgery;   Radiation: radiation therapy
Sponsors:   University Hospitals, Leicester;   National Cancer Institute (NCI);   Children's Cancer and Leukaemia Group;   Societe Francaise Oncologie Pediatrique;   European Organization for Research and Treatment of Cancer;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany;   Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria;   Swiss Group for Clinical Cancer Research;   EBMT Solid Tumors Working Party;   Children's Oncology Group
Recruiting - verified March 2010

Condition:   HIV Infections
Intervention:  
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified May 2009

Condition:   Breast Cancer
Interventions:   Drug: letrozole;   Other: placebo
Sponsors:   NCIC Clinical Trials Group;   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   International Breast Cancer Study Group;   Eastern Cooperative Oncology Group;   Southwest Oncology Group;   Cancer and Leukemia Group B;   European Organization for Research and Treatment of Cancer
Recruiting - verified June 2009